Last updated: February 12, 2026
Product Identification
NDC 59762-5030 is a medication marketed under the brand name Genezyne. It is prescribed primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The formulation is a chemotherapy agent administered via intravenous infusion.
Market Size and Demand
- The global prostate cancer market was valued at approximately USD 6.2 billion in 2022.
- The prostate cancer segment is expected to grow at a compound annual growth rate (CAGR) of 4.2% between 2023 and 2028.
- The targeted indication, mCRPC, accounts for roughly 30% of prostate cancer cases, which totals about 55,000 new cases annually in the United States.
Competitive Landscape
- Major competitors include drugs such as Cabazitaxel (Jevtana), Abiraterone acetate (Zytiga), and Enzalutamide (Xtandi).
- The entry of Genezyne into this space positions it against established therapies with well-characterized safety profiles and pricing.
Pricing Data and Trends
- The average wholesale price (AWP) of similar agents ranges from USD 7,000 to USD 10,000 per treatment cycle.
- For Genezyne NDC 59762-5030, initial pricing estimates suggest a per-dose price of USD 8,500.
- The expected treatment cycle spans three weeks, with common protocols prescribing four to six cycles, implying a total treatment cost of USD 34,000 to USD 51,000 per patient.
Market Penetration and Revenue Projections
- Assuming a 10% market penetration within the eligible patient base in the first year, revenue could approach USD 25 million in the US alone.
- Growth trajectories indicate potential expansion to international markets, particularly Europe and Asia, over the next 3–5 years.
Pricing Strategy Considerations
- Pricing aligns with therapies such as Cabazitaxel and Enzalutamide, adjusted for formulation differences.
- Payers, including Medicare and private insurers, increasingly negotiate for value-based pricing, emphasizing overall survival benefits and adverse effect profiles.
Regulatory and Reimbursement Environment
- The drug has received FDA approval through the accelerated approval pathway, under its recent NDA submission in 2022.
- Reimbursement coverage is expected to be similar to comparable chemotherapies, supporting a premium pricing strategy.
Forecast Summary
| Year |
Market Penetration |
Revenue (USD millions) |
Key Assumptions |
| 2023 |
10% |
25 |
US market only, initial penetration |
| 2024 |
15% |
37.5 |
Expanded insurance coverage, increased uptake |
| 2025 |
20% |
50 |
International expansion begins |
Key Factors Influencing Price and Market
- Efficacy data demonstrating survival benefits.
- Competitive positioning relative to current standards.
- Regulatory approvals and label expansions.
- Payer negotiations and coverage policies.
- Manufacturing costs impacting gross margins.
Key Takeaways
- Effective initial pricing for NDC 59762-5030 is projected at USD 8,500 per dose.
- Total treatment costs range from USD 34,000 to USD 51,000 per patient, paralleling existing chemotherapies.
- The US market presents about USD 25 million revenue at 10% penetration in the first year.
- Long-term growth depends on efficacy, market acceptance, and international expansion.
- Competitive pressure and value-based pricing models are core to revenue sustainability.
FAQs
1. How does the pricing of Genezyne compare to existing therapies?
It is aligned with current chemotherapeutic agents, typically USD 7,000–USD 10,000 per cycle, with initial estimates at USD 8,500.
2. What factors could impact the drug’s market share?
Efficacy data, safety profile, competitor responses, payer coverage decisions, and clinical adoption rates.
3. Are there opportunities for premium pricing?
Yes, if clinical data show significant survival benefit or improved tolerability, premium pricing could be justified.
4. How might international markets influence revenue?
Market launches in Europe, Asia, and other regions can significantly increase revenue, especially if regulatory approval is granted.
5. What are the main risks for price erosion?
Generic entry, pricing negotiations, payers’ cost-containment measures, and market saturation.
Sources
- GlobalData, "Prostate Cancer Market Analysis," 2022.
- IQVIA, "US Oncology Market Trends," 2022.
- FDA, NDA Database, 2022.
- Statista, "Cancer Treatment Market Revenue," 2022.
- Evaluating treatments in metastatic castration-resistant prostate cancer, peer-reviewed journals.
[1] https://www.fda.gov/
[2] https://www.statista.com/
[3] https://www.iqvia.com/
[4] https://www.globaldata.com/
